Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Gene editing has been in and out of the news since Crispr hit the headlines a decade ago. It’s been anything from the next big thing to a borderline miracle to a…
In September of 2022, GSK and Spero Therapeutics entered into an exclusive license agreement for late-stage antibiotic asset, Tebipenem HBr.
Got 10 minutes (well, 12 if we’re being precise)? Grab a cuppa and listen to our latest podcast diving into some of the big catalysts we’ll be looking out for in the…
Missed our webinar on orphan drugs and the impact of the Inflation Reduction Act? Well, you missed a lot but here are a few takeaways to help you catch up. And the full…
In February of 2021, Emmaus Life Sciences and Kainos Medicine entered into an agreement to jointly develop Kainos’ patented IRAK4 inhibitor (KM10544).
Our PD(L)anner reports are now hitting the airwaves.
In this edition of Meet the Team, we’re chatting to someone who is bordering on national treasure territory. Lisa Urquhart is the editor of Evaluate Vantage where she…
300 million people worldwide are living with a rare disease. The "orphan" drugs created to treat them have been a fast-growing part of the pharma market for…
It’s Meet the Team time again and to kick off 2023 we’re hopping across the pond to meet one of our US-based team members, Tom Moore, SVP Account Management - Americas.…
Missed out latest webinar? Fear not, here are three things we learned from the 2023 Preview discussion. And the webinar is available on demand now.